Skip to main content

PMV Pharmaceuticals, Inc.

corporate_fare Company Profile

PMV Pharmaceuticals, Inc.

PMVP·NASDAQ·Life Sciences·CIK 0001699382

We are a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies that target p53. Our approach leverages over four decades of research into p53, a tumor suppressor protein, to create a platform that generates selective, small molecule therapies. These therapies are designed to structurally correct specific mutant p53 proteins, which are found in approximately half of all cancers, to restore their normal function. Our lead product candidate is rezatapopt, an orally available small molecule. Rezatapopt is designed to potently and selectively correct p53 misfolding caused by the p53 Y220C mutation, while not affecting normal p53. The p53 Y220C mutation is associated with approximately 1% of all cancers, including endometrial, breast, non-small cell lung cancer (NSCLC), colorectal, pancreatic, and approximately 3% of ovarian cancers. Rezatapopt aims to restore the normal p53 structure by occupying a specific pocket created by this mutation. We are pursuing a tumor-agnostic development strategy for rezatapopt. We initiated a Phase 1/2 clinical trial, PYNNACLE, in October 2020. Our strategy is to seek approval through an accelerated pathway, and we believe the Phase 2 portion of the PYNNACLE trial could serve as a pivotal study. In October 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to rezatapopt for treating patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for PMVP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PMVP spans 8-K, 10-Q, 424B5, DEF 14A.

Recent high-impact activity:

  • Rezatapopt Posts 48% ORR in Pivotal Ovarian Analysis; PMV Pharma Targets Q1 2027 NDA
  • Rezatapopt Hits 48% Response Rate in Platinum-Resistant Ovarian Cancer; NDA Set for Q1 2027
  • PMV Pharma's Q3 10-Q Clears Going Concern Warning, Cash Runway Now Into Q1 2028
  • PMV Pharma Posts $34.4M Q3 Loss as Cash Runway Tightens
  • PMV Pharma Finalizes $50.8M Offering with FDA-Linked Warrant Reset Terms

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$77.74M
Diluted EPS
-$1.48
Op. Cash Flow
-$73.58M
Free Cash Flow
-$73.61M
Operating Income
-$86.21M
Cash & Equivalents
$37.98M
Debt / Equity
0.00×
Shares Outstanding
53.33M sh
Source: 10-K · filed 2026-03-06 · accession 0001193125-26-095014

Short Interest & Short Volume

5.62 days to cover

FINRA reported short interest of 2,153,550 shares in PMVP as of the October 30, 2026 settlement, a 5.8% decrease from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 56.7% of PMVP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,153,550 shares as of October 30, 2026
Change vs prior period▼ 5.8%
Days to cover5.62 at avg daily volume of 383,345
Daily short volume (FINRA facilities)56.7% of 2,856,425 shares on November 20, 2026
5-day average short volume54.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PMVP, detected from its recent SEC filings · based on capital-structure filings through 2026-09-01.

1 recent capital raiseATM program

Underwritten Offering with Warrants · NDA-Triggered Warrant Reset

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$0.91 +3.88% today
52-week range · as of 2026-11-20 $0.66 – $1.91
Market cap
$66.17M
Volume
4.8M (8.3× avg)
3-mo avg 584.4K
Live data · 2026-11-21 12:10 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PMVP - Latest Insights

PMVP
Nov 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.876
Real-time Price: $0.910 info
Change: +$0.034 (+4%) info
Market Cap: $66.168M info
PMVP
Nov 20, 2026, 10:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.910 info
Change: -$0.290 (-24%) info
Market Cap: $66.168M info
PMVP
Nov 10, 2026, 8:02 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $0.910 info
Change: -$0.340 (-27%) info
Market Cap: $66.168M info
PMVP
Nov 10, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $0.910 info
Change: -$0.3495 (-28%) info
Market Cap: $66.168M info
PMVP
Sep 01, 2026, 6:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.910 info
Change: -$0.360 (-28%) info
Market Cap: $66.168M info
PMVP
Sep 01, 2026, 6:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.910 info
Change: -$0.360 (-28%) info
Market Cap: $66.168M info
PMVP
Aug 31, 2026, 11:03 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.19
Real-time Price: $0.910 info
Change: -$0.280 (-24%) info
Market Cap: $66.168M info
PMVP
Aug 31, 2026, 4:25 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.910 info
Change: -$0.140 (-13%) info
Market Cap: $66.168M info
PMVP
Aug 31, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.02
Real-time Price: $0.910 info
Change: -$0.112 (-11%) info
Market Cap: $66.168M info
PMVP
Aug 31, 2026, 4:02 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.910 info
Change: -$0.1105 (-11%) info
Market Cap: $66.168M info
PMVP
Aug 14, 2026, 8:11 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.22
Real-time Price: $0.910 info
Change: -$0.305 (-25%) info
Market Cap: $66.168M info
PMVP
Aug 14, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.22
Real-time Price: $0.910 info
Change: -$0.305 (-25%) info
Market Cap: $66.168M info
PMVP
May 12, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $0.910 info
Change: -$0.4989 (-35%) info
Market Cap: $66.168M info
PMVP
May 12, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $0.910 info
Change: -$0.4989 (-35%) info
Market Cap: $66.168M info
PMVP
Apr 22, 2026, 8:01 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $0.910 info
Change: -$0.550 (-38%) info
Market Cap: $66.168M info
PMVP
Mar 06, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.910 info
Change: -$0.620 (-41%) info
Market Cap: $66.168M info
PMVP
Mar 06, 2026, 8:01 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.53
Real-time Price: $0.910 info
Change: -$0.620 (-41%) info
Market Cap: $66.168M info
PMVP
Mar 04, 2026, 9:12 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $0.910 info
Change: -$0.590 (-39%) info
Market Cap: $66.168M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets